Embecta Corp. (NASDAQ:EMBC - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.13 and traded as low as $5.98. Embecta shares last traded at $6.09, with a volume of 715,677 shares trading hands.
Analysts Set New Price Targets
Separately, Weiss Ratings raised Embecta from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, November 2nd. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Reduce" and a consensus target price of $11.00.
View Our Latest Analysis on EMBC
Embecta Stock Down 1.0%
The company has a market capitalization of $345.06 million, a P/E ratio of 4.11 and a beta of 0.81. The firm has a fifty day simple moving average of $6.01 and a 200-day simple moving average of $6.13.
Insider Transactions at Embecta
In other news, Director Milton Mayo Morris sold 6,293 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the transaction, the director owned 53,828 shares of the company's stock, valued at approximately $316,508.64. The trade was a 10.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by insiders.
Institutional Trading of Embecta
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pathstone Holdings LLC boosted its stake in shares of Embecta by 2.6% during the 3rd quarter. Pathstone Holdings LLC now owns 71,246 shares of the company's stock worth $419,000 after purchasing an additional 1,819 shares during the period. Fifth Third Bancorp boosted its stake in shares of Embecta by 44.2% in the third quarter. Fifth Third Bancorp now owns 7,061 shares of the company's stock worth $40,000 after buying an additional 2,163 shares during the last quarter. Allworth Financial LP lifted its position in shares of Embecta by 234.1% during the 3rd quarter. Allworth Financial LP now owns 4,707 shares of the company's stock valued at $27,000 after buying an additional 3,298 shares in the last quarter. GAMMA Investing LLC boosted its stake in Embecta by 101.5% during the 3rd quarter. GAMMA Investing LLC now owns 10,898 shares of the company's stock worth $62,000 after purchasing an additional 5,490 shares during the last quarter. Finally, State of Wyoming raised its holdings in shares of Embecta by 61.5% during the 1st quarter. State of Wyoming now owns 24,587 shares of the company's stock worth $217,000 after acquiring an additional 9,366 shares during the period. 93.83% of the stock is owned by hedge funds and other institutional investors.
About Embecta
(
Get Free Report)
Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals. The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business's history of developing injection devices for diabetes care. Embecta serves customers in markets around the world.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.